9-Methyl-β-carboline

Polanski lab's 2007-2020 preclinical work (rat + primary cell culture) shows 9-Me-BC does an unusually long list of useful things to the dopaminergic system at once: upregulates tyrosine hydroxylase, doubles BDNF + 3.2× artemin in astrocytes, increases hippocampal dopamine + dendritic outgrowth + spatial-learning performance, rescues MPP+-damaged dopaminergic neurons (~50% restoration after Parkinson's-model toxin insult), inhibits MAO-A (IC50 1 μM, primary) and MAO-B (15.5 μM, secondary), and exerts anti-inflammatory effects on microglia. Zero human trials. Biohacker reports at 5-15 mg/day are mixed-positive (mild dopaminergic lift, motivation, anti-anhedonia over weeks; ~30-40% feel nothing). Documented UVA-photosensitization with DNA damage in cell models is a non-theoretical concern. For Dylan: WATCH-LIST. The mechanism is genuinely interesting but the V5 stack (cerebrolysin, bromantane, semax/adamax, low-dose selegiline) covers the same axes with human safety data 9-Me-BC will not have for years. Don't be the one who finds out 9-Me-BC + 6 hours of Arizona sun = melanoma.

What β-carbolines are (and why "9-methyl" matters)

β-carbolines are tricyclic pyridoindole alkaloids found endogenously in human brain and many plants (Banisteriopsis caapi / ayahuasca's harmine + harmaline, Peganum harmala / Syrian rue, also coffee, tobacco, grilled meat). The β-carboline "core" (9H-pyrido[3,4-b]indole) is structurally related to tryptamine and shares the indole nucleus with serotonin. β-carbolines are biologically active across an unusually broad pharmacology: MAO inhibition, benzodiazepine-receptor binding (some are inverse agonists at GABA-A BZ site), DNA intercalation, mitochondrial effects, dopaminergic neurotoxicity (the 2,9-dimethyl-β-carbolinium variant is a Parkinson-relevant neurotoxin) AND, in the case of 9-Me-BC specifically, dopaminergic neuroprotection.

The 9-methyl substitution (a methyl group on the indole nitrogen) is the structural feature that, per Polanski and Wagner et al., flips the molecule from neurotoxic-to-neutral (norharman, harman) to actively neurotrophic. This is mechanistically unusual — most β-carboline pharmacology is liability-leaning, but 9-methylation appears to confer a genuinely different signaling profile.

The five-arm mechanism (preclinical)

1. Tyrosine hydroxylase (TH) upregulation in dopaminergic neurons. TH is the rate-limiting enzyme in dopamine synthesis (tyrosine → L-DOPA). In primary mesencephalic culture (Hamann et al. 2008, Polanski et al. 2010), 9-Me-BC at 90 μM (peak of bell-shaped curve, 48 hours) increased the number of TH-immunoreactive dopaminergic neurons by ~33%. The mechanism is not new neuron birth — it is conversion of pre-existing dopa-decarboxylase-positive neurons into TH-positive functional dopaminergic neurons, plus increased TH protein and mRNA in those neurons, plus induction of TH-relevant transcription factors Gata2, Gata3, Creb, and Crebbp. The PI3K/Akt pathway is required — the PI3K inhibitor LY-294002 completely abolishes the TH effect, while D2/D3 receptor antagonism (sulpiride) does not. Concentrations >125 μM lose the effect (bell-shaped, similar to NSI-189's hippocampal-volume curve).

2. Astrocyte-mediated neurotrophic factor expression. Wernicke et al. 2010, Keller et al. 2020 (PMC8592951): 9-Me-BC applied to cortical dopaminergic astrocyte cultures increased gene expression of:

• BDNF: 2-fold (the headline neurotrophic finding)
• Artemin (Artn): 3.2-fold (a GDNF-family neurotrophic factor specifically supporting dopaminergic neurons)
• Neurotrophin-3 (NT-3): 1.8-fold
• Skp1: 1.5-fold (an E3 ligase component relevant to α-synuclein turnover — Parkinson's-mechanistic)
• NCAM1: 1.4-fold (cell adhesion molecule, synaptogenesis-relevant)
• TGF-β2: 1.4-fold (anti-inflammatory + neurotrophic)

This is a multi-trophic-factor signature unusual in small molecules — most BDNF-inducers are isolated to BDNF alone. The astrocyte-mediated framing matters because astrocytes are a primary source of brain neurotrophic support, and 9-Me-BC's effect appears to operate by recruiting astrocytic support of dopaminergic neurons rather than acting directly on the neurons.

3. MAO-A and MAO-B inhibition (DUAL — biohacker writeups often misstate this as "MAO-B selective"). Keller 2020 (J Neural Transm): IC50 1 μM for MAO-A and 15.5 μM for MAO-B. This is 15.5× more potent at MAO-A than MAO-B — the molecule is, in MAO-inhibition terms, MAO-A-preferential, the opposite of selegiline's profile. At chronic biohacker doses (5-15 mg/day) measured plasma concentrations have not been published for any human, so whether either IC50 is reached in vivo is unknown. The MAO-A inhibition is the part of the mechanism that creates the theoretical tyramine-reaction and serotonin-syndrome concerns — although at the human doses used, MAO-A inhibition is likely partial and the practical risk is unquantified, the textbook MAO-A pharmacology argues for dietary caution (no aged cheese, no fermented soy) and avoidance of serotonergic drug stacking (SSRIs, SNRIs, tramadol, MDMA, high-dose dextromethorphan).

4. Anti-inflammatory microglial modulation. 9-Me-BC inhibits proliferation of activated microglia and shifts the microglial phenotype toward an anti-inflammatory M2-like state in cell-culture models (Polanski 2010). Anti-neuroinflammatory effects are mechanistically relevant to both Parkinson's pathology and (relevant for Dylan) chronic subconcussive-impact neuroinflammation from MMA training.

5. Mitochondrial complex I rescue / putative biogenesis support. In rats pretreated with the mitochondrial complex-I-poisoning Parkinson's-model neurotoxin MPP+, 9-Me-BC restored mitochondrial complex I activity by ~80% relative to MPP+-only controls. The encyclopedia framing of "AMPK → PGC-1α biogenesis" is plausible mechanistically but is a class-level extrapolation rather than 9-Me-BC-specific data — direct AMPK / PGC-1α measurements in 9-Me-BC-treated tissue are limited in the published literature. Flag (accuracy): mitochondrial biogenesis is in the prior encyclopedia note but is more inference-from-class than 9-Me-BC-direct.

6. Hippocampal dopamine + dendritic + synaptic effects. Gruss et al. 2012 (J Neurochem, PMID 22380576): rats treated with 9-Me-BC showed elevated hippocampal dopamine, improved spatial learning in the radial arm maze, and increased dendrite outgrowth and synaptic proliferation in the dentate gyrus. This is the cognitive-enhancement-relevant arm — hippocampal dopamine is involved in memory consolidation, and dendritic complexity is a structural correlate of learning. The dentate-gyrus effect overlaps NSI-189's claimed mechanism (though by a different molecular route). Whether the dentate-gyrus effect represents true adult neurogenesis (new neuron birth from progenitors) or only dendritic remodeling of existing neurons is not fully clarified in the published data — the radial-maze and dendrite findings are robust; "neurogenesis" framing is consistent with but not definitively proven by these assays.

7. α-synuclein reduction. Reported in Parkinson's-model preclinical work — 9-Me-BC reduces α-synuclein protein levels (mechanism may include Skp1 upregulation → enhanced ubiquitin-proteasome turnover of α-syn). Disease-relevant for PD mechanism; less directly relevant for a healthy 20yo.

Pharmacokinetics — the empty box

Almost no human PK data exists. The Polanski-lab work is animal-only. From the limited animal + biohacker-inferred data:

• Half-life: Estimated 15-24 hours (biohacker-community estimate, not published human PK). Long enough for once-daily dosing.
• Onset: Effects reported by users within 2-7 days of starting (consistent with gene-expression mechanism, similar to bromantane's 5-7 day onset).
• Bioavailability: Unknown for humans. Oral, sublingual, and intranasal routes are all reported in biohacker use. Sublingual administration causes documented taste/sweetness loss (likely local lingual nerve effect from prolonged β-carboline contact).
• Metabolism: Likely hepatic, but enzymology not characterized in humans.
• BBB penetration: Yes (effects in brain require it; lipophilicity of the methylated β-carboline is consistent).

This is a meaningful data gap. Every dose recommendation in the biohacker literature is extrapolated from rat dosing using allometric scaling — there is no published human Cmax, no published time-to-peak, no published human half-life, no published bioavailability for any route.